Literature DB >> 21622184

MicroRNA-regulated transgene expression systems for gene therapy and virotherapy.

Fuminori Sakurai1, Kazufumi Katayama, Hiroyuki Mizuguchi.   

Abstract

For safe and effective gene therapy, targeted tissue-restricted transgene expression is desirable. Various methods have been developed to achieve such expression, including the use of tissue-specific promoters. In addition to these approaches, a new system which can regulate transgene expression, including viral gene expression, by exploiting microRNAs (miRNAs) has recently been developed. miRNAs are approximately 22-nucleotide (nt)-long non-coding RNAs that translationally suppress or catalytically degrade target mRNA through binding to imperfectly complementary sequences in the 3'-untranslated region (UTR). In miRNA-regulated transgene expression systems, tandem copies of sequences perfectly complementary to the miRNAs are usually incorporated into the 3'-UTR of the transgene expression cassette, leading to the suppression of transgene expression in cells expressing the corresponding miRNAs. miRNA-mediated regulation of transgene expression was first demonstrated for lentivirus vectors, and subsequently this technology was applied to replication-incompetent adenovirus vectors, tumor-specific oncolytic viruses for cancer therapy, and recombinant live attenuated viruses for vaccine therapy. The aim of this review is to highlight the applications of miRNA-regulated transgene expression systems for gene therapy and virotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622184     DOI: 10.2741/3861

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  7 in total

Review 1.  MicroRNA-regulated viral vectors for gene therapy.

Authors:  Anja Geisler; Henry Fechner
Journal:  World J Exp Med       Date:  2016-05-20

2.  MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.

Authors:  Amy H Lin; Nina Timberlake; Christopher R Logg; Yanzheng Liu; Shuichi Kamijima; Oscar Diago; Kenneth Wong; Dawn K Gammon; Derek Ostertag; Katrin Hacke; Emily C Yang; Harry Gruber; Noriyuki Kasahara; Douglas J Jolly
Journal:  Hum Gene Ther       Date:  2014-06-18       Impact factor: 5.695

3.  An Enterovirus-Like RNA Construct for Colon Cancer Suicide Gene Therapy.

Authors:  Mahsa Rasekhian; Ladan Teimoori-Toolabi; Safieh Amini; Kayhan Azadmanesh
Journal:  Iran Biomed J       Date:  2015-06-06

4.  Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds.

Authors:  Michael Behr; Johanna K Kaufmann; Patrick Ketzer; Sarah Engelhardt; Martin Mück-Häusl; Pamela M Okun; Gabriele Petersen; Frank Neipel; Jessica C Hassel; Anja Ehrhardt; Alexander H Enk; Dirk M Nettelbeck
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

5.  Targeted expression of suicide gene by tissue-specific promoter and microRNA regulation for cancer gene therapy.

Authors:  Ravikanth Danda; Gopinath Krishnan; Kalaivani Ganapathy; Uma Maheswari Krishnan; Khetan Vikas; Sailaja Elchuri; Nivedita Chatterjee; Subramanian Krishnakumar
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

6.  Transcriptional targeting of primary and metastatic tumor neovasculature by an adenoviral type 5 roundabout4 vector in mice.

Authors:  Zhi Hong Lu; Sergey Kaliberov; Rebecca E Sohn; Lyudmila Kaliberova; David T Curiel; Jeffrey M Arbeit
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

7.  MicroRNA-regulated non-viral vectors with improved tumor specificity in an orthotopic rat model of hepatocellular carcinoma.

Authors:  J A Ronald; R Katzenberg; C H Nielsen; H J Jae; L V Hofmann; S S Gambhir
Journal:  Gene Ther       Date:  2013-05-30       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.